Proton Capital Corp. announced strategic alliance with PharmaChoice Canada Inc. In addition, the Strategic Alliance Agreement includes, but is not limited to, the following schedules which have been executed but are being held in escrow until the completion of the Qualifying Transaction: a license agreement, a right-of-first-refusal agreement and a master membership agreement. Under to the terms of the License Agreement, PharmaChoice Canada Inc. has granted Proton the right to use the names "PharmaChoice", "PharmaChoix", "Rx PharmaChoice, "Advice for Life" and "Rx Health Med", together with other such names as PharmaChoice Canada Inc. may operate in the future; under the terms of the ROFR, Proton receives a right-of-first -refusal to acquire PharmaChoice Canada Inc. bannered pharmacies under certain conditions applicable to such ROFRs as pharmacies come to market in the normal course of business; and under the terms of the Master Membership Agreement, all pharmacies acquired by Proton shall be required to: i) remain a PharmaChoice Canada Inc. banner pharmacy, if such is the case at the time of acquisition; ii) if not a PharmaChoice Canada Inc. ban partnered pharmacy at acquisition by Proton, such acquired pharmacy must be transitioned to a PharmaChoice Canada Inc. Bannered name, and iii) all Proton acquisitions must source their pharmaceutical supplies through PharmaChoice Canada Inc. distribution agreements with its suppliers.

If and when definitive agreements are executed in relation to the Potential QT Acquisition or Potential Financing, Proton will issue a subsequent news release in accordance with the policies of the TSXV including details of the definitive agreements and additional terms and conditions of the Qualifying Transaction, including information relating to the acquisition of a pharmacy or pharmacies, summary financial information and other information in respect of such acquisition, proposed terms of any concurrent private placement, and the proposed directors, officers, andiders of the resulting issuer upon completion of the Qualifying Transaction.